Oklo Shares Surge 8.43% on $1.55B Volume, Ranking 47th in U.S. Turnover as Institutional Demand Drives Clean Energy Momentum

Generated by AI AgentAinvest Volume Radar
Thursday, Sep 11, 2025 7:34 pm ET1min read
OKLO--
Aime RobotAime Summary

- Oklo shares surged 8.43% on Sept. 11 with $1.55B volume, driven by institutional demand for clean energy infrastructure.

- Strategic partnerships and a Southwest U.S. utility contract accelerated Oklo’s reactor commercialization and SMR validation.

- Increased options volatility and divergent performance from uranium peers highlight Oklo’s niche in advanced nuclear energy.

. 11, , . stocks by turnover. The nuclear energy firm’s shares saw heightened institutional activity amid renewed investor interest in clean energy infrastructure projects.

Recent developments highlight strategic partnerships advancing Oklo’s reactor technology commercialization timeline. A key contract award for grid integration testing with a major utility provider in the SouthwestLUV-- U.S. was cited as a catalyst, though specific financial terms were not disclosed. .

. 20. , . , .

To run this back-test rigorously I first need a few clarifications: 1. Universe: Which exchange / universeUPC-- of stocks should be screened each day? • All U.S. common stocks (NYSE + NASDAQ + Amex) • A specific index membership (e.g., S&P 1500, Russell 3000) • Something else 2. Trade mechanicsMCHB-- • Entry: buy at today’s close or tomorrow’s open? • Exit: sell at tomorrow’s close or tomorrow’s open? • Equal-weight each of the 500 names? 3. Costs / slippage: Should we include commissions or a bid-ask spread assumption? 4. Capital base: Any fixed capital (e.g., USD 1 million) or use 100% of capital each day? Once I have this information I can build the data-retrieval plan and run the back-test for you.

Hunt down the stocks with explosive trading volume.

Latest Articles

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet